SG Americas Securities LLC lessened its position in Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) by 66.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,037 shares of the company’s stock after selling 23,882 shares during the quarter. SG Americas Securities LLC’s holdings in Pacira BioSciences were worth $919,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also added to or reduced their stakes in PCRX. UMB Bank N A MO bought a new position in Pacira BioSciences in the fourth quarter valued at $25,000. First Horizon Advisors Inc. grew its stake in shares of Pacira BioSciences by 143.6% during the fourth quarter. First Horizon Advisors Inc. now owns 436 shares of the company’s stock valued at $26,000 after buying an additional 257 shares during the last quarter. Spire Wealth Management bought a new position in shares of Pacira BioSciences during the first quarter valued at about $38,000. Financial Management Professionals Inc. bought a new position in shares of Pacira BioSciences during the first quarter valued at about $69,000. Finally, Point72 Hong Kong Ltd grew its stake in shares of Pacira BioSciences by 1,800.0% during the fourth quarter. Point72 Hong Kong Ltd now owns 1,748 shares of the company’s stock valued at $105,000 after buying an additional 1,656 shares during the last quarter.
Insiders Place Their Bets
In other Pacira BioSciences news, Director Paul J. Hastings sold 533 shares of the firm’s stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $56.95, for a total value of $30,354.35. Following the completion of the sale, the director now directly owns 7,179 shares in the company, valued at $408,844.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Pacira BioSciences news, Director Paul J. Hastings sold 533 shares of the firm’s stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $56.95, for a total transaction of $30,354.35. Following the completion of the transaction, the director now owns 7,179 shares of the company’s stock, valued at $408,844.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jonathan Slonin sold 924 shares of the firm’s stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $57.19, for a total transaction of $52,843.56. Following the transaction, the insider now directly owns 37,387 shares of the company’s stock, valued at approximately $2,138,162.53. The disclosure for this sale can be found here. Insiders sold 55,505 shares of company stock worth $3,369,804 over the last three months. Company insiders own 6.10% of the company’s stock.
Wall Street Analysts Forecast Growth
Pacira BioSciences Stock Performance
Shares of PCRX opened at $56.56 on Monday. The company has a debt-to-equity ratio of 1.03, a current ratio of 2.19 and a quick ratio of 1.85. Pacira BioSciences, Inc. has a one year low of $45.05 and a one year high of $82.16. The company has a 50-day simple moving average of $57.52 and a two-hundred day simple moving average of $64.89. The firm has a market capitalization of $2.57 billion, a PE ratio of 67.33 and a beta of 0.90.
Pacira BioSciences (NASDAQ:PCRX – Get Rating) last issued its quarterly earnings data on Wednesday, May 4th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.04). Pacira BioSciences had a return on equity of 15.17% and a net margin of 6.62%. The company had revenue of $157.99 million during the quarter, compared to analysts’ expectations of $155.08 million. During the same quarter last year, the business earned $0.37 earnings per share. The business’s quarterly revenue was up 32.7% on a year-over-year basis. On average, analysts anticipate that Pacira BioSciences, Inc. will post 2.69 EPS for the current fiscal year.
Pacira BioSciences Company Profile
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.
- Get a free copy of the StockNews.com research report on Pacira BioSciences (PCRX)
- Use These To Find Your Stock’s Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter’s Up For Third Week In A Row: What’s Next For The Stock?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.